Hepatitsi Awareness Month

Responding to the Silent Epidemic: Hepatitis C

Publication Date: May 14, 2020

Erin L. Winstanley, Ph.D.

If not us, who? And if not now, when? –Ronald Regan

Hepatitis C (HCV), a blood-borne virus that infects the liver, is the “Silent Epidemic” that has been looming in the shadow of the opioid epidemic for more than a decade. In 2008, drug overdose became the leading cause of injury death in the United States (Paulozzi et al. 2012). A year earlier, the number of the deaths caused by HCV exceeded those caused by HIV (Ly et al. 2012). Individuals with HIV are now able to live significantly longer because of antiretroviral therapy (ART) and medications that can prevent HIV infection, yet these medications are not curative like those for HCV. Direct-acting antiretroviral (DAA) medications, taken once a day for 12 weeks, can eliminate the virus in ~95% of treated individuals. Those at great risk of HCV infection, however, may not realize the benefits of these life-sustaining medications.

Read the complete feature article in the May 2020 issue of the ATTC Messenger.

For free training on hepatitis C prevention and treatment, visit the ATTC Network resource,  HCV Current 

Find out more about Hepatitis C Awareness Month 2020